Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Island Pharmaceuticals Ltd ( (AU:ILA) ) has provided an announcement.
Island Pharmaceuticals Ltd has requested and been granted a trading halt on its ordinary shares on the ASX, effective from the start of trading on 2 February 2026, as it prepares to release an announcement related to US FDA feedback on its Galidesivir program. The halt, which is intended to help the company manage its disclosure obligations and maintain an orderly market, will remain in place until either the announcement is released or normal trading resumes on 4 February 2026, signalling that the forthcoming FDA-related update could be material for investors and the company’s development pipeline.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australia-based biotechnology company listed on the ASX (ASX: ILA), focused on developing pharmaceutical candidates, including its Galidesivir program, which is progressing through interactions with the US Food & Drug Administration (FDA).
Average Trading Volume: 550,642
Technical Sentiment Signal: Buy
Current Market Cap: A$104.9M
See more data about ILA stock on TipRanks’ Stock Analysis page.